Karachi: BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has announced the launch of a new human insulin product branded as "Ferulin." The designated market category for this news is pharmaceuticals and healthcare. This development was reported in compliance with Sections 96 and 131 of the Securities Act, 2015, and Clause 5.6.1(a) of the Pakistan Stock Exchange (PSX) Rule Book. According to information available from the Pakistan Stock Exchange (PSX), the launch of Ferulin is a significant event, as it marks the company's dedication to combating diabetes and broadening its array of medical products available in the market. The product, which adheres to the highest quality standards, aims to provide an effective and affordable treatment option for diabetes patients throughout Pakistan.

BF Biosciences, recognized as the first biotech plant in Pakistan, has a longstanding commitment to producing essential medicines for diseases such as HCV, cancer, cardiology, among other therapeutic areas. With over a decade in operation, the launch of Ferulin is expected to significantly enhance the subsidiary's growth and reinforce Ferozsons Laboratories' mission to meet the unmet medical needs of patients.

The announcement is directed to all TREC Holders of the Exchange to ensure widespread dissemination of this crucial development in the pharmaceutical sector.